Activity of human recombinant CYP4F3B assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP4F12 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Drug metabolism in human liver microsomes assessed as CYP3A4-mediated (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 25 uM after 120 mins by LC-MS/MS analysis
Drug metabolism in human liver microsomes assessed as CYP2J2-mediated (3R,3aS,4S,4aR,7R,8aR,9aR)-7-amino-4-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-3-methyldecahydronaphtho[2,3-c]furan-1(3H)-one formation at 25 uM after 120 mins by LC-MS/MS analysis
Activity of human recombinant CYP1A1 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP1A2 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2A6 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP1B1 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2B6 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2C8 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2C9 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2C18 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2C19 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2D6 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP2E1 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP3A5 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP4A11 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP4F2 assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH
Activity of human recombinant CYP4F3A assessed as enzyme-mediated drug metabolism treated with 25 uM vorapaxar after 120 mins by LC-MS/MS analysis in presence of NADPH